Intrahepatic cholangiocarcinoma has poor survival due to frequent recurrence and limited prognostic markers. Here, the authors identify two prognostic proteomic tumor clusters, validate a classifier across independent cohorts, and introduce EIF4A1 inhibition as a potential therapeutic strategy.
- Tilman Werner
- Johanna Thiery
- Oliver Schilling
